biology of aml developing from mds vs. de novo aml, and new targets for therapy
Published 9 years ago • 750 plays • Length 17:53Download video MP4
Download video MP3
Similar videos
-
20:12
mpn transformation to mds and aml: risk factors, therapy and outcomes
-
20:58
mpn transformation to mds and aml: risk factors, therapy, and outcomes
-
6:33
myelodysplastic syndromes - causes, symptoms, diagnosis, treatment, pathology
-
6:35
understanding aml
-
23:39
why mpn transforms to aml
-
26:15
polycythemia vera | my blood cancer diagnosis
-
1:02:28
treatment update: myelodysplastic syndromes (mds)
-
20:01
primary myelofibrosis - overview (presentation, pathophysiology, investigation, treatment)
-
7:44
the biology of secondary aml and therapy-related aml - part 1
-
10:15
acute myeloid leukemia | clinical presentation
-
23:38
why mpns transform to aml
-
34:15
from mds to aml: what every patient needs to know 11/28/17
-
1:41
the future of aml and mds diagnosis and treatment
-
24:37
current understanding of a genetic/epigenetic basis of mds
-
1:16
developing an understanding of disease progression in mds and aml
-
21:55
a unified approach to lower risk mds: standard and emerging therapies
-
1:40:23
from mds to aml: understanding the pathology, diagnostics, and genetic relationship 10/10/17
-
13:47
myelodysplastic syndrome (mds) - a precursor to acute myeloid leukemia (aml) ?! - hematology series
-
20:58
new findings and improved outcomes in the treatment of aml
-
52:20
acute myeloid leukemia: incorporating novel treatment approaches into clinical pathways
-
2:06
what factors contribute to the development of therapy-related aml or mds?